
Halozyme Therapeutics (Fri, May 03, 2024)

Buy candidate since May 02, 2024 Gain 0.23%



StockInvest.us Gyneju st. 14, "ROCKIT" Vilnius, LT-01109 Lithuania

#5771/30045

Trend:	Buy
MV Long:	Buy
MV Short:	Buy
Pivot:	Sel
Volume:	Buy
MACD:	Buy

Tech commentaries:

The Halozyme Therapeutics stock price gained 0.226% on the last trading day (Friday, 3rd May 2024), rising from \$39.82 to \$39.91. It has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated 2.39% from a day low at \$39.79 to a day high of \$40.74. The price has risen in 8 of the last 10 days and is up by 3.29% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 79 thousand more shares were traded than the day before. In total, 883 thousand shares were bought and sold for approximately \$35.24 million.

The stock lies in the middle of a wide and weak rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 6.21% during the next 3 months and, with a 90% probability hold a price between \$38.47 and \$46.17 at the end of this 3-month period.

The Halozyme Therapeutics stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock, but the stock has a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections down, there will be some support from the lines at \$38.99 and \$39.60. A breakdown below any of these levels will issue sell signals. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume is rising along with the price. This is considered to be a good technical signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Tuesday, March 12, 2024, and so far it has fallen -4.86%. Further fall is indicated until a new bottom pivot has been found.

Halozyme Therapeutics finds support from accumulated volume at \$39.72 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. On the upside the stock meets some resistance just above today's level from accumulated volume at \$40.08, \$40.79 and \$40.86.

This stock is usually traded at a good volume, and with minor daily changes, the risk is considered to be low. During the last day, the stock moved \$0.95 (2.39%) between high and low. For the last week, the stock has had daily average volatility of 3.14%.

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for **Halozyme Therapeutics** stock to perform well in the short-term.

Risk: Low

Evaluation: Buy Candidate